Medigus Ltd ADR Insiders

MDGSDelisted Stock  USD 2.36  0.15  6.79%   
Medigus employs about 77 people. The company is managed by 23 executives with a total tenure of roughly 161 years, averaging almost 7.0 years of service per executive, having 3.35 employees per reported executive. Breaking down Medigus' management performance can provide insight into the firm performance.
Christopher Rowland  CEO
CEO and Director
Nissim Darvish  Chairman
Chairman of the Board
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Medigus Management Team Effectiveness

The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities.

Medigus Workforce Comparison

Medigus Ltd ADR is rated below average in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 3,671. Medigus holds roughly 77.0 in number of employees claiming about 2.1% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.09) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.09.

Medigus Ltd ADR Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Medigus Ltd ADR Price Series Summation is a cross summation of Medigus price series and its benchmark/peer.

Medigus Notable Stakeholders

A Medigus stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medigus often face trade-offs trying to please all of them. Medigus' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medigus' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher RowlandCEO and DirectorProfile
Nissim DarvishChairman of the BoardProfile
Menashe SonnenscheinVice President - OperationsProfile
Yaron ZilbermanVice President - Sales and MarketingProfile
Gilad MamlokCFOProfile
Efrat VenkertExternal DirectorProfile
Anat NaschitzDirectorProfile
Ori HershkovitzExternal DirectorProfile
Yair RabinovitchDirectorProfile
Eitan MachoverIndependent DirectorProfile
Oded YatzkanDirector of Fin. and Accounting and VPProfile
Jeremy StarkweatherDirector of Sales, Director of Marketing-United StatesProfile
Yuval YanaiDirectorProfile
Aviel ShapiraMedical DirectorProfile
Yair RabinowitchDirectorProfile
Erez HaimovitzDirectorProfile
Doron BirgerDirectorProfile
Minelu SonnenscheinVP of OperationsProfile
Ilan OrenExecutive OfficerProfile
Yaron SilbermanChief LtdProfile
Liron CarmelChief OfficerProfile
Tali DinarChief OfficerProfile
Tatyana YossefControllerProfile

About Medigus Management Performance

The success or failure of an entity such as Medigus Ltd ADR often depends on how effective the management is. Medigus management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medigus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medigus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel. Medigus operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
The data published in Medigus' official financial statements usually reflect Medigus' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Medigus Ltd ADR. For example, before you start analyzing numbers published by Medigus accountants, it's critical to develop an understanding of what Medigus' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Medigus' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Medigus' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Medigus' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medigus Ltd ADR. Please utilize our Beneish M Score to check the likelihood of Medigus' management manipulating its earnings.

Medigus Workforce Analysis

Traditionally, organizations such as Medigus use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medigus within its industry.

Medigus Manpower Efficiency

Return on Medigus Manpower

Revenue Per Employee1.2M
Revenue Per Executive4M
Net Loss Per Employee131.1K
Net Loss Per Executive439K
Working Capital Per Employee190K
Working Capital Per Executive636.1K
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Medigus Stock

If you are still planning to invest in Medigus Ltd ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigus' history and understand the potential risks before investing.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Commodity Directory
Find actively traded commodities issued by global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets